Related references
Note: Only part of the references are listed.Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases
Antonio Pea et al.
ANNALS OF SURGERY (2020)
Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors
Alessandra Pulvirenti et al.
HPB (2019)
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future
Akihiro Ohmoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Laura H. Tang et al.
CLINICAL CANCER RESEARCH (2016)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors
Nitya Raj et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Francesca Spada et al.
NEUROENDOCRINOLOGY (2016)
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
M. Pavel et al.
NEUROENDOCRINOLOGY (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials
Pamela L. Kunz et al.
PANCREAS (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Gemcitabine and Oxaliplatin or Alkylating Agents for Neuroendocrine Tumors: Comparison of Efficacy and Search for Predictive Factors Guiding Treatment Choice
Anne-Sophie Dussol et al.
CANCER (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Genetics of pancreatic neuroendocrine tumors: implications for the clinic
Antonio Pea et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas A Clinicopathologic Analysis of 44 Cases
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)